Nham, Amy and Le, John N and Thomas, Shawn A and Gressick, Kimberly and Ussery, Emily N and Ko, Jean Y and Gladden, R Matt and Mikosz, Christina A and Schier, Joshua G and Vivolo-Kantor, Alana and Fiorillo, Maria and McMaster, McKenna and Magana, Darlene Nolasco and Verklan-McInnes, Livia and Wahl, Michael and Wood, Taylor and Adams, Axel and Krotulski, Alex and Trecki, Jordan and Ellison, Ross and Gerona, Roy and Arunkumar, Ponni and Mir, Mojde and Wise, Leslie M and Betancourt, Emma and Monty, Kathleen and Gulmatico, Jhoanna and Pojas, Angie and Fitzgerald, Ruchi and Hua, Miao (2025) Overdoses involving medetomidine mixed with opioids - Chicago, Illinois, May 2024. MMWR. Morbidity and mortality weekly report , 74 , (15) , pp. 258-265.

MEDICRIME Unit, Directorate General: Human Rights and Rule of Law. (2025) An assessment of publicly reported incidents of illicit diversion and falsification of medicines. Strasbourg: European Commission.

United Kingdom. Home Office. (2025) UK circular 002/2025: The Misuse of Drugs Act 1971 Order 2024. Changes to the Misuse of Drugs Act 1971 to control 22 substances, with 2-benzyl benzimidazole variants (nitazenes) falling under a new generic definition. London: Home Office.

Jiang, Xinyi and Connolly, Sarah and Strahan, Andrea E and Rivera Blanco, Liz and Mikosz, Christina A and Guy, Gery P and Dowell, Deborah (2024) Reported xylazine use among adults aged ≥18 years evaluated for substance use treatment - United States, July 2022-September 2023. MMWR. Morbidity and Mortality Weekly Report , 73 , (26) , pp. 594-599.

UNODC Laboratory and Scientific Service. (2024) Current NPS threats volume VII. Vienna: United Nations Office on Drugs and Crime.

European Union Drugs Agency. (2024) Harm reduction – the current situation in Europe (European Drug Report 2024). URL: https://www.euda.europa.eu/publications/european-d...

Society for the Study of Addiction. Calder, Robert (2024) Addiction audio. Season 2, 2024. London: Society for the Study of Addiction.

Center for Forensic Science Research & Education. US public alerts: Medetomidine rapidly proliferating across USA — implicated in recreational opioid drug supply & causing overdose outbreaks. (20 May 2024)

Public Health Scotland. (2024) Scotland. Public health alert: Xylazine – newly detected drug. Edinburgh: Public Health Scotland.

Edinoff, Amber N and Sall, Saveen and Upshaw, William C and Spillers, Noah J and Vincik, LeighAnn Y and De Witt, Adalyn S and Murnane, Kevin S and Kaye, Adam M and Kaye, Alan D (2024) Xylazine: a drug adulterant of clinical concern. Current Pain and Headache Reports , 28 , pp. 417-426.

[RTE radio] , Byrne, Claire ‘Zombie’ drug xylazine found in UK vapes – could it be here? (10 Apr 2024)

Advisory Council on the Misuse of Drugs. (2024) A review of the evidence on the use and harms of xylazine, medetomidine and detomidine. London: Advisory Council on the Misuse of Drugs.

Cano, Manuel and Daniulaityte, Raminta and Marsiglia, Flavio (2024) Xylazine in overdose deaths and forensic drug reports in US States, 2019-2022. JAMA Network Open , 7 .

Dahan, Albert and Franko, Thomas S and Carroll, James W and Craig, David S and Crow, Callie and Galinkin, Jeffrey L and Garrity, Justin C and Peterson, Joanne and Rausch, David B (2024) Fact vs. fiction: naloxone in the treatment of opioid-induced respiratory depression in the current era of synthetic opioids. Frontiers in Public Health , 12 .

Copeland, Caroline S and Rice, Kathleen and Rock, Kirsten L and Hudson, Simon and Streete, Peter and Lawson, Alexander J and Couchman, Lewis and Holland, Adam and Morley, Stephen (2024) Broad evidence of xylazine in the UK illicit drug market beyond heroin supplies: Triangulating from toxicology, drug-testing and law enforcement. Addiction , 119 , (7) , pp. 1301-1309.

Sue, Kimberly L and Hawk, Kathryn (2024) Editorial. Clinical considerations for the management of xylazine overdoses and xylazine-related wounds. Addiction , 119 , (4) , pp. 606-608.

Krotulski, Alex J and Manini, Alex F and Schwarz, Evan and Walton, Sara E and Fogarty, Melissa F and Logan, Barry K (2023) Medetomidine – NPS Discovery new drug monograph. United States: Center for Forensic Science Research and Education.

Nahar, Limon K and Andrews, Rebecca and Paterson, Sue (2023) Rapid response: Evolving use of recreational drugs in UK – Nitazenes and Xylazine. BMJ , 383 , p. 2280.

Zagorski, Claire M and Hosey, Rebecca A and Moraff, Christopher and Ferguson, Aaron and Figgatt, Mary and Aronowitz, Shoshana and Stahl, Natalie E and Hill, Lucas G and McElligott, Zoe and Dasgupta, Nabarun (2023) Reducing the harms of xylazine: clinical approaches, research deficits, and public health context. Harm Reduction Journal , 20 .

European Monitoring Centre for Drugs and Drug Addiction. (2023) Most recent data from the European Syringe Collection and Analysis Project Enterprise (ESCAPE): data explorer, analysis and key findings. URL: https://www.emcdda.europa.eu/publications/data-fac...

WEDINOS. (2023) PHILTRE annual report April 2022 - March 2023. Cardiff: WEDINOS.

Addiction Technology Transfer Center Network. (2023) Understanding Xylazine: an emerging concern. Kansas: Addiction Technology Transfer Center Network.

Rock, Kirsten L and Lawson, Alexander J and Duffy, Joanne and Mellor, Alice and Treble, Ric and Copeland, Caroline S (2023) The first drug-related death associated with xylazine use in the UK and Europe. Journal of Forensic and Legal Medicine , 97 .

International Narcotics Control Board. (2023) Report of the International Narcotics Control Board for 2022. Vienna: United Nations.

Harm Reduction International. (2022) The global state of harm reduction 2022. London: Harm Reduction International.

Krotulski, Alex J and Shinefeld, Jennifer and DeBord, Joshua and Logan, Barry K (2022) Fentanyl purity, potency, & synthesis: real-time testing of opioid drug products in the United States. USA: Center for Forensic Science Research and Education.

Centre on Drug Policy Evaluation. (2022) What’s contaminating Toronto’s drug supply? insights from samples checked by Toronto’s drug checking service January 1 - December 31, 2021. Toronto: Centre on Drug Policy Evaluation.

Canadian Centre on Substance Use and Addiction. (2022) CCENDU drug alert: Xylazine. Ottawa: Canadian Centre on Substance Use and Addiction.